Mesoblast 2020 Full Year Financial Results Webcast
Mesoblast Limited (Nasdaq:MESO) plans to host a webcast on August 26, 2020, at 6 PM EDT to present its financial and operational highlights for FY2020, ending June 30, 2020. The company focuses on developing allogeneic cellular medicines for inflammatory diseases and has received FDA priority review for RYONCIL™ to treat pediatric acute graft versus host disease, with a potential U.S. launch in 2020. Mesoblast is conducting Phase 3 trials for advanced heart failure and chronic low back pain and has commercial partnerships in Europe and China.
- FDA priority review acceptance for RYONCIL™ for pediatric acute GVHD.
- Potential launch of RYONCIL™ in the U.S. expected in 2020.
- Ongoing Phase 3 trials for advanced heart failure and chronic low back pain.
- None.
NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will host a webcast to discuss its financial and operational highlights for the fourth quarter and full-year ended June 30, 2020 (FY2020).
The webcast will begin at 6pm EDT Wednesday, August 26; 8am AEST Thursday, August 27, 2020.
It can be accessed via https://webcast.boardroom.media/mesoblast-limited/20200826/NaN5f2ba898ed347b00198de987
The webcast will also be available on the Investor page of the Company’s website: www.mesoblast.com
About Mesoblast
Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Mesoblast’s Biologics License Application to seek approval of its product candidate RYONCIL™ (remestemcel-L) for pediatric steroid-refractory acute graft versus host disease (acute GVHD) has been accepted for priority review by the United States Food and Drug Administration (FDA), and if approved, product launch in the United States is expected in 2020. Remestemcel-L is also being developed for other inflammatory diseases in children and adults including moderate to severe acute respiratory distress syndrome. Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast
Release authorized by the Chief Executive.
| For further information, please contact: | |
| Media | |
| Julie Meldrum | Kristen Bothwell |
| T: +61 3 9639 6036 | T: +1 917 613 5434 |
| E: julie.meldrum@mesoblast.com | E: kbothwell@rubenstein.com |
| Investors | |
| Schond Greenway | Paul Hughes |
| T: +212 880 2060 | T: +61 3 9639 6036 |
| E: schond.greenway@mesoblast.com | E: paul.hughes@mesoblast.com |
FAQ
What is the date of Mesoblast's FY2020 highlights webcast?
What is RYONCIL™ and its significance for Mesoblast?
What trials is Mesoblast currently conducting?
What markets has Mesoblast established partnerships in?
